טוען...
BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
BRAF inhibitor monotherapy appears to be ineffective in BRAF(V600E)-positive colorectal cancer (CRC) as a result of inherent EGFR-mediated resistance mechanisms. This concept initiated combinatorial treatment approaches. Nevertheless, BRAF inhibition in isogenic CRC cell lines induced enhanced cell-...
שמור ב:
| הוצא לאור ב: | Mol Cell Oncol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4905336/ https://ncbi.nlm.nih.gov/pubmed/27308494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2014.1002709 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|